NewsSource: EClinCloud

Don't Let Scale Translation Delay Your Timeline

4 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

►►►

Do you also need to set aside time for scale translation?

  //  

Article illustration


In recent years, a growing number of registrational clinical studies have been conducted in China, and relevant regulatory authorities have placed increasingly stringent requirements on study quality. Studies frequently use many scales; however, the original versions of many commonly used scales are not in Chinese, so sponsors need to account for scale translation in project planning. For trials that require clinical outcome assessment (COA) data as efficacy or safety endpoints, study teams should, whenever possible, adopt a thorough translation process for scales to ensure standardization and measurement equivalence. This is a very time-consuming process.

 

In addition, if scales need to be administered on electronic devices and managed through an eCOA system, even more time must be set aside. All too often, however, study teams underestimate the time required for this process, which affects the overall study timeline and ultimately delays key milestones.

 

Therefore, sound project planning, comprehensive consideration of the key factors affecting project timelines, and early initiation of implementation can effectively prevent protocol deviations caused by translation.


►►►

How are scale translation and electronic implementation carried out?

1

Understand the key factors affecting project timelines

Project timelines vary depending on the specific characteristics of each study, but all projects need to consider the following key factors:


  • Scale acquisition

  • Volume of scales and content requiring translation and electronic implementation

  • Availability of existing language versions ready for commercial use

  • Availability of electronic versions ready for commercial use

2

The electronic implementation process for scales

Licensing → Design → System Build → Certification


For scales without a pre-existing electronic format, the study team must first obtain the scale in the source language (usually US or UK English) along with the license, and then design and build the eCOA system. This process takes approximately 6-8 weeks. Additional time must also be reserved to obtain certification from the scale copyright holder and conduct patient acceptance testing.


During this process, the scale management teams at EClinCloud and Signant Health can leverage their existing relationships with copyright holders to obtain scales and their licenses on behalf of sponsors and convert them into electronic formats.

3

Translation and linguistic validation

At this stage, subsequent translation work can begin. For language translation, EClinCloud collaborates with professionally qualified and experienced medical translation teams to oversee the entire linguistic validation process. Following ISPOR recommendations, the process includes translation, back-translation, cultural adaptation, and psychometric validation. Although labor-intensive, this process meets regulatory requirements and ensures that the translated documents are presented in the same manner as the source documents, enabling users to fully understand the study-related information. This is critical for ensuring the reliability of study endpoints.


Once translation is complete, the Chinese version of the scale can be stored in electronic form so that it can be deployed directly and rapidly in other studies that require the same scale.

►►►

Professional teams supporting your project

To ensure the integrity of these processes and meet project deadlines, sponsors are advised to begin collaborating with all project stakeholders early to jointly develop a practical and realistic timeline.


EClinCloud and Signant Health provide sponsors and CROs with experienced project teams, as well as an eCOA scientific team composed of clinical and technical experts, delivering accurately translated scales and electronic tools with thoroughly validated reliability and validity to support the smooth conduct of clinical studies.


As a global leader in eCOA and endpoint assessment, Signant Health is headquartered in the United States and has more than 1700 employees across three continents. With deep expertise across therapeutic areas, it has earned the trust and collaboration of hundreds of sponsors and CROs, including all of the top 20 pharmaceutical companies.


As the exclusive representative for Signant's business operations in Greater China, EClinCloud brings leading clinical development services to sponsors and CROs seeking technology to improve data collection quality.


EClinCloud scale services

Article illustration

With an extensive scale library and an experienced team of experts, EClinCloud provides one-stop scale services:

  1. Has a professional medical team to interpret the protocol and determine the accurate scale version;

  2. Has an extensive scale library and has established strong working relationships with multiple scale copyright holders for rapid response;

  3. Has extensive eCOA implementation experience, with experience in large international projects across every stage, including copyright management, scale migration, device rental and maintenance, and data analysis and reporting;

  4. Provides scale translation and linguistic validation services, including translation, reconciliation, back-translation, and cultural adaptation;

  5. Provides scale digitization services, making scale assessment and information collection more efficient and convenient.

Click to view specific EClinCloud scale management services:

Service Overview | Scale Management



Article illustration


Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.